NS057715/NS/NINDS NIH HHS/United States[Grant Number] - Search Results

Year	Number of Results
2007	1
2008	1
2009	2
2010	3
2011	4
2012	8
2013	1
2016	2
2022	0

1

Kynurenines in the mammalian brain: when physiology meets pathology.

Schwarcz R, Bruno JP, Muchowski PJ, Wu HQ. Schwarcz R, et al. Nat Rev Neurosci. 2012 Jul;13(7):465-77. doi: 10.1038/nrn3257. Nat Rev Neurosci. 2012. PMID: 22678511 Free PMC article. Review.

2

Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease.

Thevandavakkam MA, Schwarcz R, Muchowski PJ, Giorgini F. Thevandavakkam MA, et al. CNS Neurol Disord Drug Targets. 2010 Dec;9(6):791-800. doi: 10.2174/187152710793237430. CNS Neurol Disord Drug Targets. 2010. PMID: 20942784 Review.

3

Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease.

Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ. Schwarcz R, et al. Prog Neurobiol. 2010 Feb 9;90(2):230-45. doi: 10.1016/j.pneurobio.2009.04.005. Epub 2009 Apr 24. Prog Neurobiol. 2010. PMID: 19394403 Free PMC article. Review.

4

Kynurenic acid and 3-hydroxykynurenine production from D-kynurenine in mice.

Wang XD, Notarangelo FM, Wang JZ, Schwarcz R. Wang XD, et al. Brain Res. 2012 May 21;1455:1-9. doi: 10.1016/j.brainres.2012.03.026. Epub 2012 Mar 17. Brain Res. 2012. PMID: 22498176 Free PMC article.

5

Tryptophan-2,3-dioxygenase (TDO) inhibition ameliorates neurodegeneration by modulation of kynurenine pathway metabolites.

Breda C, Sathyasaikumar KV, Sograte Idrissi S, Notarangelo FM, Estranero JG, Moore GG, Green EW, Kyriacou CP, Schwarcz R, Giorgini F. Breda C, et al. Proc Natl Acad Sci U S A. 2016 May 10;113(19):5435-40. doi: 10.1073/pnas.1604453113. Epub 2016 Apr 25. Proc Natl Acad Sci U S A. 2016. PMID: 27114543 Free PMC article.

6

Mutant huntingtin impairs immune cell migration in Huntington disease.

Kwan W, Träger U, Davalos D, Chou A, Bouchard J, Andre R, Miller A, Weiss A, Giorgini F, Cheah C, Möller T, Stella N, Akassoglou K, Tabrizi SJ, Muchowski PJ. Kwan W, et al. J Clin Invest. 2012 Dec;122(12):4737-47. doi: 10.1172/JCI64484. Epub 2012 Nov 19. J Clin Invest. 2012. PMID: 23160193 Free PMC article.

7

Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration.

Zwilling D, Huang SY, Sathyasaikumar KV, Notarangelo FM, Guidetti P, Wu HQ, Lee J, Truong J, Andrews-Zwilling Y, Hsieh EW, Louie JY, Wu T, Scearce-Levie K, Patrick C, Adame A, Giorgini F, Moussaoui S, Laue G, Rassoulpour A, Flik G, Huang Y, Muchowski JM, Masliah E, Schwarcz R, Muchowski PJ. Zwilling D, et al. Cell. 2011 Jun 10;145(6):863-74. doi: 10.1016/j.cell.2011.05.020. Cell. 2011. PMID: 21640374 Free PMC article.

8

Drosophila eye color mutants as therapeutic tools for Huntington disease.

Green EW, Campesan S, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, Kyriacou CP, Giorgini F. Green EW, et al. Fly (Austin). 2012 Apr-Jun;6(2):117-20. doi: 10.4161/fly.19999. Epub 2012 Apr 1. Fly (Austin). 2012. PMID: 22634544

9

Enzymatic transamination of D-kynurenine generates kynurenic acid in rat and human brain.

Pérez-de la Cruz V, Amori L, Sathyasaikumar KV, Wang XD, Notarangelo FM, Wu HQ, Schwarcz R. Pérez-de la Cruz V, et al. J Neurochem. 2012 Mar;120(6):1026-35. doi: 10.1111/j.1471-4159.2012.07653.x. Epub 2012 Feb 2. J Neurochem. 2012. PMID: 22224417 Free PMC article.

10

The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease.

Campesan S, Green EW, Breda C, Sathyasaikumar KV, Muchowski PJ, Schwarcz R, Kyriacou CP, Giorgini F. Campesan S, et al. Curr Biol. 2011 Jun 7;21(11):961-6. doi: 10.1016/j.cub.2011.04.028. Curr Biol. 2011. PMID: 21636279 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results